FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme - a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy.

The US #FDA has approved a fourth product via its new National #PriorityVoucher Programme - a 7.2 mg dose of #NovoNordisk's weight loss drug Wegovy (#semaglutide), to be marketed as #WegovyHD.

pharmaphorum.com/news/fda-app...